Pfizer Inc.

NYSE:PFE Stock Report

Market Cap: US$149.4b

Pfizer Management

Management criteria checks 3/4

Pfizer's CEO is Albert Bourla, appointed in Jan 2019, has a tenure of 5.92 years. total yearly compensation is $21.56M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $8.77M. The average tenure of the management team and the board of directors is 5.9 years and 7.8 years respectively.

Key information

Albert Bourla

Chief executive officer

US$21.6m

Total compensation

CEO salary percentage8.3%
CEO tenure5.9yrs
CEO ownership0.006%
Management average tenure5.9yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call

Dec 18

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Dec 16
Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Dec 11

Pfizer: Too Cheap To Ignore

Dec 05

Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

Nov 21

Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer

Nov 15

Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Nov 13
Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

Nov 08

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 01
Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

Oct 29

Pfizer: Activists Clouding A Promising Picture

Oct 21

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

Oct 08

Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

Oct 01

There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Sep 23
There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Sep 23

CEO Compensation Analysis

How has Albert Bourla's remuneration changed compared to Pfizer's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 29 2024n/an/a

US$4b

Jun 30 2024n/an/a

-US$3b

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$22mUS$2m

US$2b

Oct 01 2023n/an/a

US$10b

Jul 02 2023n/an/a

US$21b

Apr 02 2023n/an/a

US$29b

Dec 31 2022US$33mUS$2m

US$31b

Oct 02 2022n/an/a

US$30b

Jul 03 2022n/an/a

US$29b

Apr 03 2022n/an/a

US$25b

Dec 31 2021US$24mUS$2m

US$22b

Oct 03 2021n/an/a

US$19b

Jul 04 2021n/an/a

US$12b

Apr 04 2021n/an/a

US$9b

Dec 31 2020US$21mUS$2m

US$7b

Sep 27 2020n/an/a

US$212m

Jun 28 2020n/an/a

US$7b

Mar 29 2020n/an/a

US$9b

Dec 31 2019US$18mUS$2m

US$11b

Sep 29 2019n/an/a

US$16b

Jun 30 2019n/an/a

US$13b

Mar 31 2019n/an/a

US$11b

Dec 31 2018US$10mUS$1m

US$4b

Sep 30 2018n/an/a

US$24b

Jul 01 2018n/an/a

US$23b

Apr 01 2018n/an/a

US$22b

Dec 31 2017US$9mUS$1m

US$21b

Compensation vs Market: Albert's total compensation ($USD21.56M) is above average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.

CEO

Albert Bourla (62 yo)

5.9yrs

Tenure

US$21,562,064

Compensation

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and serves as its Chairman and director of the Board since January 2020 and had been its Executive D...

Leadership Team

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO5.9yrsUS$21.56m0.0059%
$ 8.8m
David Denton
Chief Financial Officer & Executive VP2.6yrsUS$5.28m0.00067%
$ 1.0m
Mikael Dolsten
Chief Scientific Officer and President of Research & Development5.9yrsUS$8.86m0.0057%
$ 8.5m
Douglas Lankler
Executive VP & General Counsel11yrsUS$5.48m0.0026%
$ 3.9m
Jennifer Damico
Senior VP4.8yrsno data0.00015%
$ 224.1k
Lidia Fonseca
Executive VP and Chief Digital & Technology Officer5.9yrsno datano data
Francesca DeMartino
Chief Investor Relations Officerno datano datano data
Rady Johnson
Executive VP and Chief Compliance11yrsno data0.0018%
$ 2.7m
Payal Becher
Chief People Experience Officer & Executive VP4.5yrsno data0.00063%
$ 941.1k
Sally Susman
Executive VP & Chief Corporate Affairs Officer16.8yrsno data0.0029%
$ 4.3m
Michael Vincent
Senior VP and Chief Scientific Officer of Inflammation & Immunology8.6yrsno datano data
Chris Boshoff
Executive VP & Chief Oncology Officerno datano data0.0028%
$ 4.1m

5.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: PFE's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO4.9yrsUS$21.56m0.0059%
$ 8.8m
Shantanu Narayen
Lead Independent Director11.3yrsUS$430.00kno data
Ronald Blaylock
Independent Director7.8yrsUS$380.00k0.00023%
$ 343.6k
Suzanne Nora Johnson
Independent Director17.3yrsUS$410.00k0.00018%
$ 268.9k
James Smith
Independent Director10.5yrsUS$390.00k0.000060%
$ 89.6k
Charles Hagel
Member of Emerging Markets Advisory Boardno datano datano data
Susan Hockfield
Independent Director4.8yrsUS$363.00kno data
Daniel Littman
Independent Director6.8yrsUS$391.40kno data
James Robert Quincey
Independent Director4.8yrsUS$380.00kno data
Scott Gottlieb
Independent Director5.5yrsUS$417.20k0.00018%
$ 268.9k
Joseph Echevarria
Independent Director9.5yrsUS$390.00kno data
Helen Hobbs
Independent Director13yrsUS$410.00kno data

7.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: PFE's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pfizer Inc. is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Alistair CampbellBerenberg